Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Investors Business Daily
Investors Business Daily
Technology
ALLISON GATLIN

The Generics Are Here: How Bristol Myers Squibb Expects Patent Losses To Hit In 2022

Bristol Myers Squibb reaffirmed expectations for a $10 billion pitfall from its generics-facing drugs on Wednesday, and BMY stock dipped.

The company acquired Celgene in a 2019 megamerger. Now, one of the biggest products from the deal is facing generics. During the June quarter, sales of cancer drug Revlimid toppled 22% to just north of $2.5 billion. Another cancer med, Abraxane, generated $241 million, declining 19%.

For the year, the company expects $46 billion in total sales. That includes a $10 billion or double-digit decline for Revlimid and Abraxane.

On today's stock market, BMY stock climbed 1.6% to close at 74.81.

BMY Stock: Sales, Earnings Grow

Overall, sales edged 2% higher to $11.89 billion, above analysts' projections for $11.42 billion. Excluding some items, Bristol Myers earned $1.93 per share. That also topped the $1.77 forecast, according to FactSet. Earnings climbed 18%.

Bristol Myers cited blood thinner Eliquis, immuno-oncology drug Opdivo and newer products for the sales increase. Eliquis is the company's biggest moneymaker. Sales jumped 16% higher to $3.24 billion. Opdivo sales climbed 8% to $2.06 billion.

Collectively, the drugs Bristol Myers lists as its "new product portfolio" generated $482 million in sales, more than doubling year over year.

For the year, Bristol Myers reiterated its outlook for adjusted earnings of $7.44-$7.74 per share and $46 billion in sales. BMY stock analysts expected earnings of $7.44 per share on $46.22 billion in sales.

Follow Allison Gatlin on Twitter at @IBD_AGatlin.

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.